1,415.60
-16.95
(-1.18%)
At close: April 9 at 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
266,300,500
254,466,300
224,731,800
216,233,600
189,885,200
Cost of Revenue
95,629,000
95,923,800
89,606,300
92,297,200
80,203,800
Gross Profit
170,671,500
158,542,500
135,125,500
123,936,400
109,681,400
Operating Expense
111,189,100
104,855,900
94,946,800
88,232,100
77,174,000
Operating Income
59,482,400
53,686,600
40,178,700
35,704,300
32,507,400
Net Non Operating Interest Income Expense
1,540,100
1,297,100
527,000
-267,300
-1,134,400
Pretax Income
65,757,700
57,019,000
40,383,500
34,932,700
32,900,600
Tax Provision
15,753,400
15,465,900
12,028,600
9,338,000
8,887,600
Net Income Common Stockholders
49,897,200
41,215,500
28,019,100
25,167,500
24,048,700
Diluted NI Available to Com Stockholders
49,897,200
41,215,500
28,019,100
25,167,500
24,048,700
Basic EPS
61.79
51.05
34.72
31.20
29.82
Diluted EPS
61.74
51.01
34.69
31.17
29.79
Basic Average Shares
807,455.18
807,291.69
807,007.97
806,668.28
806,358.45
Diluted Average Shares
808,184.69
807,998.98
807,627.73
807,440.95
807,296.95
Rent Expense Supplemental
--
926,500
868,600
781,800
758,600
Total Expenses
206,818,100
200,779,700
184,553,100
180,529,300
157,377,800
Net Income from Continuing & Discontinued Operation
49,897,200
41,215,500
28,019,100
25,167,500
24,048,700
Normalized Income
47,745,175.69
41,061,140.16
30,861,625.84
26,090,115.84
23,551,711.09
Interest Income
--
2,195,900
1,622,400
796,200
472,600
Interest Expense
468,300
711,300
945,600
1,048,500
1,529,800
Net Interest Income
1,540,100
1,297,100
527,000
-267,300
-1,134,400
EBIT
66,226,000
57,730,300
41,329,100
35,981,200
34,430,400
EBITDA
75,997,500
67,146,400
51,521,000
45,882,000
44,461,600
Reconciled Cost of Revenue
95,629,000
95,923,800
89,606,300
92,297,200
80,203,800
Reconciled Depreciation
9,771,500
9,416,100
10,191,900
9,900,800
10,031,200
Net Income from Continuing Operation Net Minority Interest
49,897,200
41,215,500
28,019,100
25,167,500
24,048,700
Total Unusual Items Excluding Goodwill
2,830,000
211,800
-1,450,400
-1,259,200
680,900
Total Unusual Items
2,830,000
211,800
373,800
-1,259,200
680,900
Normalized EBITDA
73,167,500
66,934,600
51,147,200
47,141,200
43,780,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
677,975.69
57,440.16
-432,074.16
-336,584.16
183,911.09
3/31/2021 - 1/1/1996
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DRREDDY.NS Dr. Reddy's Laboratories Limited
1,094.05
-1.25%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,652.20
-2.14%
ZYDUSLIFE.NS Zydus Lifesciences Limited
844.40
-1.71%
LUPIN.NS Lupin Limited
1,919.70
-3.18%
NATCOPHARM.NS NATCO Pharma Limited
746.50
-3.07%
DIVISLAB.NS Divi's Laboratories Limited
5,386.15
-0.02%
AUROPHARMA.NS Aurobindo Pharma Limited
1,058.00
-3.56%
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,376.30
-4.48%
GRANULES.NS Granules India Limited
431.10
-2.98%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,126.80
-3.69%